Peptide Comparison
GHRP-6 vs Hexarelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Two GHRPs in the same regimen: Moderate risk per peptide research literature. Ghrelin receptor (GHS-R1a) saturation + accelerated desensitization; may blunt long-term GH response.
Data-derived verdict
Hexarelin has stronger documented evidence (Phase 2 (not approved)) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Hexarelin is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: cortisol. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| GHRP-6 | Hexarelin | |
|---|---|---|
| Class | GHRP; ghrelin receptor agonist | GHRP; potent ghrelin receptor agonist |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHS-R1a agonist with strong orexigenic effect | GHS-R1a agonist; more potent GH release than other GHRPs |
| Route | SC / Intranasal | SC / Intranasal |
| Half-life | ~15-30 min | ~1 hr |
| Dosage (research) | 100-300 mcg SC 2-3x daily | 100-200 mcg SC 1-2x daily (short cycles) |
| Evidence tier | Anecdotal + Animal Studies | Phase 2 (not approved) |
| Research depth | 163 indexed | 158 indexed |
| Availability | Research Chemical | Research Chemical |
| Reported risks | Strong hunger; cortisol/prolactin rise; water retention | Cortisol/prolactin elevation; pituitary desensitization |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick GHRP-6 or Hexarelin?
Hexarelin has stronger documented evidence (Phase 2 (not approved)) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Hexarelin is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between GHRP-6 and Hexarelin?
GHRP-6 is classed as GHRP; ghrelin receptor agonist; Hexarelin is classed as GHRP; potent ghrelin receptor agonist. Reported mechanism: GHRP-6, GHS-R1a agonist with strong orexigenic effect; Hexarelin, GHS-R1a agonist; more potent GH release than other GHRPs. Reported half-life: GHRP-6, ~15-30 min; Hexarelin, ~1 hr. Routes in published studies: GHRP-6, SC / Intranasal; Hexarelin, SC / Intranasal.
Which has stronger evidence, GHRP-6 or Hexarelin?
Hexarelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHRP-6 is graded Anecdotal + Animal Studies, with 7 cited sources on its reference page and 163 indexed studies. Hexarelin is graded Phase 2 (not approved), with 4 cited sources on its reference page and 158 indexed studies.
Which is more accessible, GHRP-6 or Hexarelin?
Neither GHRP-6 nor Hexarelin is an FDA-approved drug. Catalog status: GHRP-6, Research Chemical; Hexarelin, Research Chemical. FDA lists GHRP-6 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are GHRP-6 and Hexarelin ever combined?
GHRP-6 and Hexarelin appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two GHRPs in the same regimen, moderate risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…